This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Acarbose

Alpha-glucosidase inhibitor.

Aliases (4)

Precose · Glucobay · alpha-glucosidase inhibitor · AGI

TYPICAL DOSE

—

ROUTE

—

CYCLE

—

STORAGE

—

Overview

What is Acarbose?

Alpha-glucosidase inhibitor. Blunts post-prandial glucose by blocking intestinal carb digestion. ITP-validated mouse lifespan +22% (male). Most evidence-backed longevity drug after rapamycin + metformin. WATCH-LIST for now; OPTIONAL-ADD in middle age.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Was this helpful?

Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸

Loading…

Continue: Extended research →

Our verdict, decision matrix, deep dives, controversies, sources

Related compounds

Cross-referenced from Acarbose

Biguanide / oral antihyperglycemic / longevity-candidate

STRONG-CANDIDATE

Polyamine / autophagy inducer / caloric-restriction mimetic

Gut-microbiome-derived ellagitannin metabolite (dibenzofuran-coumarin) — endogenous mitophagy inducer when microbiome converts; orally bioavailable as direct supplement bypassing the microbiome conversion step

Sodium-glucose cotransporter-2 (SGLT2) inhibitor. AstraZeneca/BMS. FDA-approved 2014 for T2D, expanded labels for heart failure (HFrEF + HFpEF), chronic kidney disease.